{"id":4484,"date":"2023-07-21T09:37:50","date_gmt":"2023-07-21T07:37:50","guid":{"rendered":"https:\/\/www.amyloidosisalliance.org\/comunicato-stampa-importante\/"},"modified":"2026-11-03T10:28:16","modified_gmt":"2026-11-03T09:28:16","slug":"comunicato-stampa-importante","status":"publish","type":"post","link":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/","title":{"rendered":"Comunicato stampa importante"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Un\u2019ottima notizia da condividere con la comunit\u00e0!! <br\/><br\/>Questo comunicato stampa annuncia che il laboratorio BioBridge potr\u00e0 presentare una domanda di autorizzazione alle autorit\u00e0 sanitarie. <br\/>Ci vorr\u00e0 tempo, e il trattamento non sar\u00e0 disponibile a breve.<\/p>\n\n<p class=\"wp-block-paragraph\"><br\/>I risultati completi saranno presentati al congresso dell\u2019ESC ad Amsterdam tra un mese.<br\/>Un nuovo trattamento \u00e8 una buona notizia e ci auguriamo che sia disponibile in tutti i paesi, per tutti i pazienti. <\/p>\n\n<p class=\"wp-block-paragraph\">Le disuguaglianze nell\u2019accesso ai trattamenti restano troppo grandi.<\/p>\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2023\/07\/BridgeBio-Press-Release-ATTRibute-CM-30-Month-Data.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Incorporamento di BridgeBio-Press-Release.\"><\/object><a id=\"wp-block-file--media-2a54c423-6ba6-434f-9ac5-0f4917b3d978\" href=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2023\/07\/BridgeBio-Press-Release-ATTRibute-CM-30-Month-Data.pdf\">BridgeBio-Press-Release<\/a><a href=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2023\/07\/BridgeBio-Press-Release-ATTRibute-CM-30-Month-Data.pdf\" class=\"wp-block-file__button wp-element-button\" download=\"\" aria-describedby=\"wp-block-file--media-2a54c423-6ba6-434f-9ac5-0f4917b3d978\">T\u00e9l\u00e9charger<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.<\/p>\n","protected":false},"author":1,"featured_media":4485,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[],"class_list":["post-4484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-it"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comunicato stampa importante<\/title>\n<meta name=\"description\" content=\"Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comunicato stampa importante\" \/>\n<meta property=\"og:description\" content=\"Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-21T07:37:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T09:28:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/\"},\"author\":{\"name\":\"Amyloidosis Alliance\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#organization\"},\"headline\":\"Comunicato stampa importante\",\"datePublished\":\"2023-07-21T07:37:50+00:00\",\"dateModified\":\"2026-11-03T09:28:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/\"},\"wordCount\":86,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/\",\"name\":\"Comunicato stampa importante\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"datePublished\":\"2023-07-21T07:37:50+00:00\",\"dateModified\":\"2026-11-03T09:28:16+00:00\",\"description\":\"Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/comunicato-stampa-importante\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comunicato stampa importante\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comunicato stampa importante","description":"Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/","og_locale":"it_IT","og_type":"article","og_title":"Comunicato stampa importante","og_description":"Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.","og_url":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_published_time":"2023-07-21T07:37:50+00:00","article_modified_time":"2026-11-03T09:28:16+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_creator":"@amyloidosisa","twitter_site":"@amyloidosisa","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#article","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/"},"author":{"name":"Amyloidosis Alliance","@id":"https:\/\/www.amyloidosisalliance.org\/it\/#organization"},"headline":"Comunicato stampa importante","datePublished":"2023-07-21T07:37:50+00:00","dateModified":"2026-11-03T09:28:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/"},"wordCount":86,"commentCount":0,"publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/#organization"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/","url":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/","name":"Comunicato stampa importante","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#primaryimage"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","datePublished":"2023-07-21T07:37:50+00:00","dateModified":"2026-11-03T09:28:16+00:00","description":"Un\u2019azienda annuncia di poter presentare un trattamento per l\u2019amiloidosi ATTR alle autorit\u00e0 sanitarie. Ora l\u2019accesso al trattamento deve raggiungere i pazienti di tutti i paesi.","breadcrumb":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#primaryimage","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.amyloidosisalliance.org\/it\/comunicato-stampa-importante\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.amyloidosisalliance.org\/it\/home\/"},{"@type":"ListItem","position":2,"name":"Comunicato stampa importante"}]},{"@type":"WebSite","@id":"https:\/\/www.amyloidosisalliance.org\/it\/#website","url":"https:\/\/www.amyloidosisalliance.org\/it\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.amyloidosisalliance.org\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.amyloidosisalliance.org\/it\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/www.amyloidosisalliance.org\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.amyloidosisalliance.org\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/posts\/4484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/comments?post=4484"}],"version-history":[{"count":1,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/posts\/4484\/revisions"}],"predecessor-version":[{"id":4486,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/posts\/4484\/revisions\/4486"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/media\/4485"}],"wp:attachment":[{"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/media?parent=4484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/categories?post=4484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/it\/wp-json\/wp\/v2\/tags?post=4484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}